AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KJUL 92 min read$ICCC

IMMUCELL CORP /DE/ (ICCC): Results of Operations and Financial Condition

IMMUCELL CORP /DE/ (ICCC) filed an SEC Form 8-K — Results of Operations and Financial Condition. iccc20260708_8k.htm false 0000811641 0000811641 2026-07-09 2026-07-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event repo

Original reporting
SEC EDGAR 8-K
Published Jul 9, 2026, 8:08 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 9, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$ICCC
Bullish
medium confidence
Mentioned
$ICCC
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ICCCBullishMed
01

Why it matters

The disclosed 11.5% YoY product sales increase can shift short-term expectations for revenue trajectory, but without audited figures or guidance it is less likely to drive a large repricing by itself.

02

Market read

A concrete, newly disclosed sales growth datapoint from a primary SEC filing can affect near-term sentiment and positioning.

03

What to watch

Traders will likely need the full Exhibit 99.1 for gross margin, product mix, cash burn, and any updated outlook; the excerpt alone is incomplete for valuation changes.

Relevance 7/10Novelty 6/10Timing: after-hours/filing today, ahead of the next earnings cycle

Background

The company filed an SEC Form 8-K (Item 2.02) announcing preliminary Q2 2026 product sales results.

Company-level read

Ticker impact

$ICCCBullishMedium confidence
Context

ImmuCell reported preliminary Q2 2026 product sales up 11.5% year over year, disclosed via an 8-K with attached press release.

Expected impact

Mildly positive bias for the next trading session, with follow-through dependent on whether the full press release adds margin, guidance, or backlog details.

Evidence & confidence

This is a primary-source filing (8-K) with a concrete sales datapoint, but it is explicitly preliminary and unaudited, and the excerpt provides no profitability or forward guidance.

Market effects

Sector

Limited read-across because the filing provides only company-specific preliminary sales growth, not sector-wide demand or regulatory changes.

Regional

No clear regional spillover indicated in the excerpt.

Global

No global macro or international transaction details provided.

Counterpoint

What could challenge this read

Preliminary, unaudited sales growth may reverse if channel inventory timing or one-off shipments drove the YoY increase.

Key entities

  • issuer
    ImmuCell Corporation

    Nasdaq-listed company filing the 8-K and reporting preliminary Q2 2026 product sales up 11.5% YoY.

Read at source← All news

Related articles

JUL 9
$ICCCMed

ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results

ImmuCell (Nasdaq: ICCC) reported preliminary, unaudited sales for Q2 2026. Total product sales were $7.2 million, up 11.5% year over year, with domestic sales up 27.7% and international down 38.9%. For the first six months, sales rose 20.9% to $17.5 million. Management will discuss results on Aug. 14, 2026.

manilatimes.net3 min
AUG 8
$INBKMedAI 8/10

First Internet Bancorp (INBK) Q2 2026 Earnings Call Transcript

First Internet Bancorp (INBK) reported Q2 2026 revenue of $41.1 million, up 23%, and non-GAAP diluted EPS of $0.27 versus $0.02 a year earlier. Net interest margin (FTE) rose to 2.47%. Credit costs eased, but net charge-offs were $16.9 million. Full-year 2026 EPS guidance is $2.35 to $2.45.

fool.com7 min
AUG 8
$KDMed

Kyndryl Q1 Earnings Call Highlights

Kyndryl (NYSE:KD) Q1 call said demand is rising for AI deployment, hybrid modernization, cybersecurity and data-residency. It reported 40 deals worth over $50M in 12 months, with 10 in Q1, and Kyndryl Consult signings up 50%. IBM relationship changes are expected to weigh on constant-currency revenue through FY2027. FCF was -$401M; cash $2.1B. Outlook FY2027 reaffirmed.

yahoo.com5 min
AUG 8
$KAIMedAI 8/10

Kadant Q2 Earnings Call Highlights

Kadant (NYSE:KAI) reported Q2 equipment backlog of $182 million and said aftermarket demand stayed at record or near-record levels. Flow Control revenue rose 5% to $100 million; Industrial Processing revenue rose to a record $144 million; Material Handling bookings were $73 million. Q2 gross margin fell to 43.8%. Kadant raised FY revenue guidance to $1.19-$1.21B and adjusted EPS to $12.43-$12.68.

yahoo.com6 min
AUG 8
$KRPMed

Kimbell Royalty Q2 Earnings Call Highlights

Kimbell Royalty (NYSE:KRP) reported record Q2 adjusted EBITDA of $84.9 million, with cash G&A of $5.9 million ($2.50 per BOE). It declared a $0.47 per common unit cash distribution, up 15% QoQ, and said 47% may be return of capital. The borrowing base rose to $660 million; debt was $478.7 million. Rig activity and production varied by basin.

yahoo.com6 min
AUG 8
$KMPRMed

Kemper Q2 Earnings Call Highlights

Kemper (NYSE:KMPR) reported Q2 results and discussed credit-loss allowances tied to surplus notes in its reciprocal exchange, including a $21 million pre-tax charge on $36 million of notes. Holding-company liquidity was $766 million and debt-to-capital rose to 28.3%. Personal auto normalized combined ratio was 102% and commercial 93.7%, with California rate actions and restructuring savings over $80 million run-rate.

yahoo.com6 min